Bio-Techne Corp (TECH, Financial) has recently captured the attention of investors and financial analysts alike, thanks to its strong financial performance and promising growth trajectory. With its shares currently priced at $82.50, Bio-Techne Corp has enjoyed a daily gain of 1.97%, and an impressive three-month increase of 22.33%. A detailed analysis, supported by the GF Score, positions Bio-Techne Corp for significant future growth.
What Is the GF Score?
The GF Score is a proprietary stock performance ranking system developed by GuruFocus. It evaluates stocks based on five key aspects: financial strength, profitability, growth, GF Value, and momentum. These aspects are weighted differently to calculate a composite score that ranges from 0 to 100, with 100 indicating the highest potential for outperformance. Bio-Techne Corp boasts a GF Score of 94, signaling strong future performance potential.
- Financial strength rank: 8/10
- Profitability rank: 9/10
- Growth rank: 9/10
- GF Value rank: 7/10
- Momentum rank: 7/10
Understanding Bio-Techne Corp's Business
Bio-Techne Corp, headquartered in Minnesota, is a prominent life sciences manufacturer that serves the pharmaceutical, biotechnology, academic, and diagnostic markets. The company operates through two main segments: protein sciences and diagnostics and genomics. Protein sciences, which account for 75% of revenue, focus on equipment and consumables for protein analysis and research antibodies. The diagnostics segment offers products for cancer assays and diagnostic manufacturers. With a market cap of $13.00 billion and annual sales of $1.15 billion, Bio-Techne Corp maintains a significant presence in the U.S. (55% of revenue) and has substantial operations in EMEA (20%), the U.K. (5%), and APAC (15%).
Financial Strength and Stability
Bio-Techne Corp's financial robustness is evident in its Interest Coverage ratio of 14.62, significantly above the benchmark favored by investment guru Benjamin Graham. Additionally, its Altman Z-Score of 12.42 indicates a strong buffer against financial distress, and a Debt-to-Revenue ratio of 0.43 showcases prudent debt management.
Profitability and Growth Metrics
The company's profitability is highlighted by an impressive Operating Margin of 24.26% in 2023, reflecting a consistent upward trend over the past five years. This growth in profitability is complemented by a 3-Year Revenue Growth Rate of 14.4%, outperforming 66.5% of its peers in the biotechnology industry.
Conclusion: A Strong Candidate for Market Outperformance
Considering Bio-Techne Corp's robust financial strength, impressive profitability, and consistent growth metrics, the GF Score underscores the company's exceptional position for potential market outperformance. Investors looking for similar opportunities can explore other high-performing companies using the GF Score Screen available to GuruFocus Premium members.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
